NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.Edward M. Schaeffer, Deborah A. Freedman-Cass, Heather H. Cheng et al.|PubMed|2022Cited by 172
Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE)Devaki Shilpa Surasi, Morand Piert, Matthias Eiber et al.|European Urology|2023Cited by 90
Diagnostic Performance and Safety of <sup>18</sup> F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)Ashesh B. Jani, Katherine Zukotynski, Gregory Ravizzini et al.|The Journal of Urology|2023Cited by 65
Impact of preoperative prostate magnetic resonance imaging on the surgical management of high-risk prostate cancerJanet Baack Kukreja, Brian F. Chapin|Prostate Cancer and Prostatic Diseases|2019Cited by 23